COVID-19 vaccination linked to lower risk for postinfection outcomes
Mar 13, 2024
A reduced risk was seen for venous thromboembolism, arterial thrombosis/thromboembolism and heart failure.
Higher use of healthcare portal seen during COVID-19 pandemic
Mar 06, 2024
Lower portal activity was linked to older age, female sex and for Hispanic/Latinx, non-Hispanic Black and other race patients.
SARS-CoV-2 omicron infection linked to increased risk for reinfection
Aug 24, 2023
Reinfected seniors had lower serum neutralizing antibodies to ancestral, omicron BA.1 SARS-CoV-2 after initial omicron infection.
Burden of neurologic diagnoses lower after COVID-19 versus flu
Mar 20, 2024
Postinfection incident neurologic diagnoses were observed in 2.79 and 4.91% of the COVID-19 and influenza cohorts, respectively.
Moderna COVID-19 vaccine tied to lower adverse event risk in older adults
Aug 11, 2023
The mRNA-1273 vaccine also was tied to greater protection against COVID-19 in older adults.
Paxlovid not helpful for reducing most post-COVID-19 conditions
Oct 31, 2023
No differences were seen in most post-COVID-19 conditions examined individually or by organ system, apart from a lower combined risk for venous thromboembolism and pulmonary embolism.
More medical lab tests will soon face federal scrutiny, FDA says
Apr 29, 2024
Laboratory tests used by millions of Americans are soon to be classified as medical devices, and as such be regulated by the US Food and Drug Administration, the agency announced Monday.
Fourth COVID-19 shot beneficial in patients with autoimmune rheumatic diseases
Nov 28, 2023
A fourth dose reduces the risk for SARS-CoV-2 for patients with systemic autoimmune rheumatic diseases using DMARDs.
Infection with omicron less likely to result in post-COVID-19 condition
Sep 18, 2023
No variation in the risk for post-COVID-19 condition was seen based on the number of vaccinations, but previous infection was linked to reduced post-COVID-19 condition risk.
Nearly half of US COVID-19 cases now caused by JN.1 variant
Dec 28, 2023
The speed at which the JN.1 variant has spread this month suggests that it may spread more easily and be better at evading the immune system.